The levels of APP and PS1 overexpression vary between amyloid mouse models because of different promoters used and local effects of genomic insertion sites, so we started by quantifying the expression of transgenic APP and PS1 relative to the endogenous mouse proteins. The gene discussed is APP; the disease is amyloidosis.